- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00079339
Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
Phase I/II Trial of R115777 and XRT in Pediatric Patients With Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To estimate the maximum tolerated dose (MTD) of R115777 administered concurrently with radiation therapy to pediatric patients with non-disseminated, diffuse, intrinsic brainstem gliomas who are not receiving enzyme-inducing anti-convulsant drugs (EIACD).
II. To assess the efficacy of R115777 treatment in combination with radiation therapy for patients with non-disseminated, diffuse, intrinsic pontine gliomas as measured by progression-free survival and survival distributions.
SECONDARY OBJECTIVES:
I. To characterize toxicities associated with R115777 treatment in combination with and post radiation therapy.
II. To characterize radiographic changes in brainstem gliomas treated with radiation and R115777 using MRI, perfusion and diffusion imaging and PET scans.
OUTLINE: This is a phase I (closed to accrual as of 1/19/06), multicenter, dose-escalation study of tipifarnib followed by a phase II safety and efficacy study.
PHASE I: Patients undergo radiotherapy 5 days a week for 6 weeks. Beginning 0-2 days before radiotherapy, patients receive oral tipifarnib twice daily until the completion of radiotherapy. Beginning 2 weeks after the completion of radiotherapy, patients receive oral tipifarnib twice daily in weeks 1-3. Treatment repeats every 4 weeks for up to 24 additional courses (total of 26 courses) in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tipifarnib during radiotherapy until the maximum tolerated dose is determined. The MTD is defined as the dose level preceding that at which 2 of 6 patients experience dose-limiting toxicity.
PHASE II: Patients undergo radiotherapy and receive tipifarnib at the MTD as in phase I (closed to accrual as of 1/19/06). Treatment continues for up to 24 months (26 courses) in the absence of disease progression or unacceptable toxicity.
FOLLOW-UP:
Phase I: Participants contributing only to the phase I part are followed for 90 days after completion of therapy. Adverse events that have not resolved within 90 days after stopping treatment will be followed until resolution.
Phase II: Participants in the phase I part treated at the MTD or participants in the phase II part are followed until the earliest of death or three years after starting treatment.
PROJECTED ACCRUAL: A total of 3-55 patients (3-18 patients for phase I [closed to accrual as of 1/19/06] and a total of 40 patients for phase II [including 6 patients treated in the dose-finding portion of phase I (closed to accrual as of 1/19/06)]) will be accrued for this study within 2.3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- Pediatric Brain Tumor Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly diagnosed non-disseminated intrinsic diffuse brainstem glioma
- Karnofsky performance scale (KPS) (for > 16 yrs of age) or Lansky performance score (LPS) (for =< 16 years of age) => 50 assessed within two weeks prior to registration
Prior/concurrent therapy:
- Chemo: No prior therapy allowed
- Radiation therapy (XRT): No prior therapy allowed
- Bone Marrow Transplant: None prior
- Anti-convulsants: Patients receiving EIACDs will not be eligible; however, patients may switch from EIACDs to non-EIACDs and must then be on non-EIACDs for a minimum of 7 days prior to registration
- Growth factors: Off all colony forming growth factor(s) > 2 weeks prior to registration (G-CSF, GM-CSF, erythropoietin)
- Absolute neutrophil count >= 1,000/mm^3
- Platelets >= 100,000/mm^3 (transfusion independent)
- Hemoglobin >= 8 gm/dL (transfusion independent)
- Serum creatinine that is less than the upper limit of institutional normal for age or GFR > 70 ml/min/1.73m2
- Bilirubin =< 1.5 time upper limit of normal for age
- SGPT (ALT) and SGOT (AST) < 2.5 times institutional upper limit of normal
- Female patients of childbearing potential must have negative serum or urine pregnancy test; patient must not be pregnant or breast-feeding
- Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study
- Signed informed consent according to institutional guidelines must be obtained
Exclusion Criteria:
- Patients must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy; patients must not have any disease that will obscure toxicity or dangerously alter drug metabolism
- Patients with disseminated intrinsic diffuse brainstem glioma
- Patients taking enzyme-inducing anticonvulsant drugs
- Patients with known allergy to topical or systemic imidazoles (e.g., clotrimazole, ketoconazole, miconazole, econazole)
- Patients receiving any other anticancer or experimental drug therapy
- Patients with uncontrolled infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (radiation therapy and tipifarnib)
PHASE I: Patients undergo radiotherapy 5 days a week for 6 weeks. Beginning 0-2 days before radiotherapy, patients receive oral tipifarnib twice daily until the completion of radiotherapy. Beginning 2 weeks after the completion of radiotherapy, patients receive oral tipifarnib twice daily in weeks 1-3. Treatment repeats every 4 weeks for up to 24 additional courses (total of 26 courses) in the absence of disease progression or unacceptable toxicity. PHASE II: Patients undergo radiotherapy and receive tipifarnib at the MTD as in phase I (closed to accrual as of 1/19/06). Treatment continues for up to 24 months (26 courses) in the absence of disease progression or unacceptable toxicity. |
Given orally
Other Names:
Undergo radiotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants in the Phase I Component With Dose-limiting Toxicities (DLTs) Observed During the First 8 Weeks (Courses 1 and 2) of Tipifarnib Therapy
Time Frame: Day 1 of tipifarnib therapy to week 8
|
The dose limiting toxicity (DLT) analysis population consists of phase I participants who developed DLT during the maximum tolerated dose (MTD) estimation period (courses 1 and 2) or who completed the MTD estimation period (courses 1 and 2) without DLTs.
DLTs observed during courses 1 and 2 were used to estimate the MTD.
|
Day 1 of tipifarnib therapy to week 8
|
Progression-free Survival (PFS)
Time Frame: Assessed before the first dose of tipifarnib, every 8 weeks for the first 48 weeks, and then every 12 weeks.
|
PFS was defined as the interval from initiation of treatment to the earliest of disease progression (tumor increase of 25% over baseline tumor measurement; appearance of new lesion(s); or progressive/worsening neurological status) or death for patients who failed, or to the last date of follow up for patients without failure.
|
Assessed before the first dose of tipifarnib, every 8 weeks for the first 48 weeks, and then every 12 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Perfusion Ratio at Two Weeks After Completion of Radiation
Time Frame: Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of treatment on changes in neuroimaging meaurements.
Neuroimaging changes may have some association with outcome (response, survival, etc.).
Perfusion values are obtained from magnetic resonance perfusion imaging and were measured at baseline, every 8 weeks for the first 48 weeks, and then every 12 weeks until treatment is discontinued.
|
Baseline and two weeks post completion of radiation
|
Change From Baseline in Diffusion Ratio at Two Weeks After Completion of Radiation.
Time Frame: Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of treatment on changes in neuroimaging meaurements.
Neuroimaging changes may have some association with outcome (response, survival, etc.).
Diffusion values are obtained from magnetic resonance diffusion imaging and were measured at baseline, every 8 weeks for the first 48 weeks, and then every 12 weeks until treatment is discontinued.
|
Baseline and two weeks post completion of radiation
|
Change From Baseline in Volume FLAIR at Two Weeks After Completion of Radiation
Time Frame: Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables.
Neuroimaging changes may have some association with outcome (response, survival, etc.).
Volume FLAIR is one parameter obtained from standard magnetic resonance imaging (MRI) studies of the brain.
Volume FLAIR was obtained at baseline and within two weeks after completion of radiation.
|
Baseline and two weeks post completion of radiation
|
Mean Tumor to Gray Matter Ratio Measured at Baseline
Time Frame: Baseline
|
This study attempts to characterize neuroimaging parameters from positron emission tomography.
For each patient, the axial image through the tumor containing the maximum activity per pixel corresponding to the highest FluoroDeoxyGlucose (FDG) uptake was identified and a region of interest (ROI) was drawn based on the FDG definition of the tumor.
The mean pixel values within the tumor ROI were normalized by those for normal gray matter to provide ratios of tumor/gray matter.
Each patient has a mean tumor to gray matter ratio value and the median of these values across patients is reported.
|
Baseline
|
Mean Tumor to White Matter Ratio Measured at Baseline
Time Frame: Baseline
|
This study attempts to characterize neuroimaging parameters from positron emission tomography.
For each patient, the axial image through the tumor containing the maximum activity per pixel corresponding to the highest FluoroDeoxyGlucose (FDG) uptake was identified and a region of interest (ROI) was drawn based on the FDG definition of the tumor.
The mean pixel values within the tumor ROI were normalized by those for normal white matter to provide ratios of tumor/white matter.
Each patient has a mean tumor to white matter ratio value and the median of these values across patients is reported.
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daphne Haas-Kogan, Pediatric Brain Tumor Consortium
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2012-03021 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- PBTC-014 (Other Identifier: CTEP)
- U01CA081457 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Untreated Childhood Brain Stem Glioma
-
National Cancer Institute (NCI)CompletedGlioblastoma | Gliosarcoma | Anaplastic Astrocytoma | Untreated Childhood Brain Stem Glioma | Giant Cell Glioblastoma | Untreated Childhood Anaplastic Astrocytoma | Untreated Childhood Giant Cell Glioblastoma | Untreated Childhood Glioblastoma | Untreated Childhood Gliosarcoma | Brain Stem Glioma | Untreated... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUntreated Childhood Brain Stem Glioma | Untreated Childhood Anaplastic Astrocytoma | Untreated Childhood Anaplastic Oligodendroglioma | Untreated Childhood Giant Cell Glioblastoma | Untreated Childhood Glioblastoma | Untreated Childhood Gliomatosis Cerebri | Untreated Childhood Gliosarcoma | Untreated...United States
-
Erik MittraNational Cancer Institute (NCI)TerminatedUntreated Childhood Brain Stem Glioma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Adult Pilocytic Astrocytoma | Adult Pineal Gland Astrocytoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUntreated Childhood Brain Stem GliomaUnited States
-
National Cancer Institute (NCI)CompletedUntreated Childhood Brain Stem GliomaUnited States
-
Sue O'DorisioNational Cancer Institute (NCI); Ride for KidsWithdrawnRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Untreated Childhood Brain Stem Glioma | Untreated Childhood Medulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Adult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Childhood... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Brain Stem Glioma | Childhood Spinal Cord Neoplasm | Childhood Oligodendroglioma | Childhood Cerebral Anaplastic AstrocytomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Recurrent Childhood... and other conditionsUnited States
Clinical Trials on tipifarnib
-
Samsung Medical CenterActive, not recruitingUrothelial CarcinomaKorea, Republic of
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Childhood... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
NYU Langone HealthNational Cancer Institute (NCI)Completed
-
University of Maryland, BaltimoreNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditionsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
University Health Network, TorontoNational Cancer Institute (NCI)Completed
-
Mayo ClinicNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States